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We read with interest the recent article by Gielen et al. and congratulate the
authors on this timely study [1]. The study processed a number of patients
divided into three groups according to the use of antiplatelet medication
within 10 days prior to surgery: (i) acetylsalicylic acid (ASA) only, (ii)
ASA + clopidogrel or (iii) no antiplatelet medication. To assess the optimal stop
day, the authors analysed the amount of blood loss within 48 h after the oper-
ation by a series of multiple linear regression models, one for each preoperative
day (from Day −10 up to −1). They concluded that there is no clinically relevant
effect on blood loss, indicating an optimal day of withdrawal for ASA alone or
in combination with clopidogrel. Nonetheless, the suspension of clopidigrel
2 days before surgery resulted in the reduction of percentage of patients receiv-
ing platelet transfusions, especially in the ASA + clopidogrel group.
The authors are to be commended for taking the initiative to challenge the
current guidelines by the evidence that discontinuation at a later day (−4 till
−1) is not life threatening and does not signiﬁcantly impact the postoperative
blood loss and the amount of blood transfusions required. As recommended
by European Society of Cardiology/European Association for Cardio-Thoracic
Surgery guidelines on myocardial revascularization, preoperative clopidogrel
should be suspended at least 5 days before surgery in elective patients referred
for coronary artery bypass graft (CABG) surgery to reduce bleeding, usage of
blood products and related complications [2]. However, guidelines have not
taken into account the wide interindividual variability in recovery time after
clopidogrel withdrawal, the wide range of individual responses to clopidogrel
and the synergistic effect of ASA + clopidogrel in terms of the degree of platelet
inhibition [3]. As a consequence, a different approach from current guidelines
could be required to determine the optimal time for CABG surgery, especially
in those patients with acute coronary syndrome who need urgent surgery and
are exposed to antiplatelet therapy with ASA + clopidogrel or clopidogrel
alone.
In our recent case–control study carried out on patients undergoing CABG
who were assuming clopidogrel, we evaluated the possibility of determining
the time of preoperative clopidogrel discontinuation using an individualized
point-of-care platelet function measurement [4]. Our results showed that moni-
toring platelet function provides an objective guideline to determine a ﬂexible
timing of surgery. This individualized strategy reduced the postoperative
bleeding and the consumption of blood products. Finally, it should be empha-
sized that we identiﬁed a number of patients with normal platelet function
despite being on an adequate dosage of clopidogrel (clopidogrel-resistant) and
patients who had a fast recovery of platelet function after discontinuation of
clopidogrel (within 2–3 days). In contrast, 20% of patients displayed persistent
platelet inhibition and required from 6 to 8 days for complete recovery of plate-
let function after clopidogrel discontinuation. In conclusion, according to sug-
gestions by the 2011 Blood Conservation Clinical Practice Guidelines from the
Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists, we
believe that the point-of-care guided preoperative administration/discontinu-
ation of antiplatelet agent could be indicated for an individual approach to
patients with the aim to reduce both bleeding and adverse events compared
with the current practice of unselected timing [5].
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